

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Product datasheet for TA385164

RFWD3 Rabbit Polyclonal Antibody

Product data:

Product Type:	Primary Antibodies
Applications:	ELISA, IHC, WB
Recommended Dilution:	WB: 1/500-1/2000 IHC: 1/100-1/300 ELISA: 1/40000
Reactivity:	Human
Host:	Rabbit
lsotype:	IgG
Clonality:	Polyclonal
Immunogen:	The antiserum was produced against synthesized peptide derived from human RFWD3. AA range:374-423
Formulation:	Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide, pH 7.3.
Concentration:	lot specific
Purification:	Affinity Chromatography
Conjugation:	Unconjugated
Storage:	Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Stability:	1 year
Predicted Protein Size:	Observed MW (kDa):85
Database Link:	Q6PCD5




This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2023 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US


GRIGENE RFWD3 Rabbit Polyclonal Antibody – TA385164

Background: Swiss-Prot Acc.Q6PCD5.E3 ubiquitin-protein ligase required for the repair of DNA interstrand cross-links (ICL) in response to DNA damage (PubMed:21504906, PubMed:21558276, PubMed:26474068, PubMed:28575657, PubMed:28575658). Plays a key role in RPA-mediated DNA damage signaling and repair (PubMed:21504906, PubMed:21558276, PubMed:26474068, PubMed:28575657, PubMed:28575658, PubMed:28691929). Acts by mediating ubiquitination of the RPA complex (RPA1, RPA2 and RPA3 subunits) and RAD51 at stalled replication forks, leading to remove them from DNA damage sites and promote homologous recombination (PubMed:26474068, PubMed:28575657, PubMed:28575658). Also mediates the ubiquitination of p53/TP53 in the late response to DNA damage, and acts as a positive regulator of p53/TP53 stability, thereby regulating the G1/S DNA damage checkpoint (PubMed:20173098). May act by catalyzing the formation of short polyubiquitin chains on p53/TP53 that are not targeted to the proteasome (PubMed:20173098). In response to ionizing radiation, interacts with MDM2 and enhances p53/TP53 ubiquitination, possibly by restricting MDM2 from extending polyubiquitin chains on ubiquitinated p53/TP53 (PubMed:20173098).

Product images:



This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2023 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US



This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2023 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US